Consent to the use of cookies

This site uses technical cookies and profiling cookies, previous users consent, to send personalized advertising communication and to allow the sending of "third party" cookies (set by a website different from the one visited). The use of cookies lasts 1 year.

This site uses technical cookies and profiling cookies, previous users consent, to send personalized advertising communication and to allow the sending of "third party" cookies (set by a website different from the one visited). The use of cookies lasts 1 year.

!

By closing the banner with the [X] button you don't allow the use of profiling cookies. Therefore, we will not be able to personalize your browsing experience, nor offering you products or services based on your preferences and online behaviors.

Click on the following link to read the full version of the Privacy-Cookie policy, to deny consent to the cookies or to customize the configuration, and to modify any choices at any time by accessing the dedicated section (Privacy – Cookie Policy).

To accept all cookies, click on the “Accept” button.

More Options
Accept
{"clientID":"2b71d197-0c21-4234-ba98-2689b888f985","signature":"664610f33aa0503128c41216cec8b65f079ea4ee9ece982d6c7d6715d0fc4e88","encryption":"68cad83b4246825bd81d4bc1059d4620","keyID":"183b753b-7f28-af43-f453-4bd93774f44a","user":"C1AAFC8C323DFDA567B3CD7D0E48C3DD","clientIDSh":"1d9f34e6-7f26-427f-a9d8-0fa45b27a1ca","signatureSh":"664610f33aa0503128c41216cec8b65f079ea4ee9ece982d6c7d6715d0fc4e88","encryptionSh":"68cad83b4246825bd81d4bc1059d4620","keyIDSh":"16eb5dfd-e4eb-6b7e-4294-8fc82de1428e","userSh":"C1AAFC8C323DFDA567B3CD7D0E48C3DD"}
Homepage
Newsroom
News
Venture Capital Nevasgr investment in Tr1X

Neva Sgr invests in US biotech firm Tr1X

The image accompanying the News on Neva Sgr's investment in the US biotech Tr1X portrays a researcher at work in a laboratory. She is wearing a lab coat, gloves and a mask and is transferring liquids between tubes.

Through its Neva First Fund, Neva Sgr has finalised an investment in Tr1X, a leading US biotech firm researching cures for autoimmune and inflammatory diseases: Tr1X aims to deliver the first clinical trial dose in 2023.

Tr1X was founded by Professor Maria Grazia Roncarolo, one of the world's leading experts in cell and gene therapy.

Neva Sgr, an Intesa Sanpaolo Group company wholly owned by Intesa Sanpaolo Innovation Center, also successfully completed the fundraising of €250 million for its Neva First Fund, dedicated to investments in highly innovative companies worldwide.

Last updated 14 October 2022 at 17:39:27

{"toolbar":[]}
Facebook Facebook YouTube YouTube Twitter Twitter LinkedIn LinkedIn Instagram Instagram
Intesa Sanpaolo
Transparency
Fondo di garanzia
per le PMI del Ministero dello Sviluppo Economico (Legge 662/96 )

Copyright 2019 © Intesa Sanpaolo